Inqovi (Decitabine and Cedazuridine)
- Medicine Name: Inqovi
- Generic Name: Decitabine and Cedazuridine
- Dosage Form & Strength: Tablets: 35 mg Decitabine and 100 mg Cedazuridine
- Manufactured By: Astex Pharmaceuticals, Inc.
Inqovi is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor, used to treat adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary myelodysplastic syndromes with the following French- American-British subtypes and intermediate-1/2, and high-risk International Prognostic Scoring System groups.
Recommended Dosage: Inqovi tablets contain 35 mg of decitabine and 100 mg of cedazuridine. The recommended dosage is 1 tablet, taken by mouth, once a daily for the first 5 days of each 28-day cycle. Tablets should be taken on an empty stomach, at least a couple of hours prior to or a couple of hours after a meal. After 5 days of treatment, you do not need to take this medicine for the next 23 days. Take your dose one time daily at approximately the same time each day. In case you miss your dose by more than 12 hours, skip that dose and extend your cycle by 1 day.
- Do not substitute inqovi 35 mg-100 mg tablets for an intravenous decitabine product within a cycle. Consider administering antiemetics before each dose in order to minimize nausea and vomiting.
- Obtain complete blood cell counts before the initiation of cedazuridine/decitabine, before each cycle, and as clinically indicated to monitor response and toxicity.
- Inqovi (cedazuridine/decitabine) can cause fetal harm in cases administered to a pregnant woman. Verify the status of pregnancy in females of reproductive potential before initiating the therapy.
- Due to the potential for serious adverse reactions in the breastfed child, women should not breastfeed during treatment with cedazuridine/decitabine and for at least 2 weeks following the last dose.
- On behalf of genotoxicity findings, males with female partners of reproductive potential should use effective contraception while on treatment with inqovi tablet and for 3 months after the final dose.
What documents are required to import INQOVI to India?
INQOVI (Decitabine and Cedazuridine) can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients id proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is INQOVI available in India?
INQOVI (Cedazuridine/Decitabine) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
INQOVI can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of INQOVI (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for Inqovi price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the INQOVI (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.